Pfizer
PFE
$25.55
-0.31%
Pfizer Inc. is one of the world's largest pharmaceutical firms, primarily engaged in the discovery, development, and commercialization of prescription drugs and vaccines, operating within the Drug Manufacturers - General industry. As a global market leader, the company is distinguished by its massive scale, extensive R&D pipeline, and a portfolio of blockbuster products like Prevnar 13, Vyndaqel, and Eliquis. The current investor narrative is dominated by the company's post-pandemic transition, marked by a significant decline in COVID-related product revenue, which has led to intense scrutiny over its ability to return to sustainable growth through new drug launches, pipeline execution, and strategic acquisitions to offset looming patent expirations.…
PFE
Pfizer
$25.55
Related headlines
Investment Opinion: Should I buy PFE Today?
Rating: Hold. The core thesis is that Pfizer is a deeply undervalued, cash-generative pharmaceutical giant facing a painful but likely temporary transition, making it suitable only for patient, income-oriented investors with a high risk tolerance regarding its dividend.
The Hold rating is supported by four specific data points: 1) A compelling forward P/E of 9.23, 2) A high dividend yield of 6.9%, 3) Strong TTM free cash flow of $9.08 billion, and 4) A manageable debt-to-equity ratio of 0.78. However, these positives are counterbalanced by a payout ratio of 125.75%, a recent quarterly revenue decline of 1.16%, and severe technical underperformance. Analyst sentiment is mixed, lacking a strong bullish catalyst.
The two biggest risks that could invalidate this thesis are a dividend cut and further revenue deceleration. This Hold rating would upgrade to a Buy if the forward P/E compressed further towards 8x on sustained earnings growth, or if the company announced a credible plan to cover the dividend with recurring free cash flow. It would downgrade to a Sell if quarterly revenue growth turns negative by more than 5% or if the dividend is reduced. The stock is fairly valued to slightly undervalued relative to its depressed earnings prospects, but overvalued if the dividend is unsustainable.
Sign up to view all
PFE 12-Month Price Forecast
The AI assessment is neutral based on a high-probability base case of stagnation. The stock's deep value (forward P/E of 9.23) and high yield provide a floor, but the unsustainable dividend and lack of revenue growth create a ceiling. The stance would upgrade to bullish on concrete evidence of core business growth (e.g., two consecutive quarters of positive organic revenue growth ex-COVID products) and a reduction in the payout ratio below 80%. It would downgrade to bearish on a dividend cut or guidance indicating a revenue decline exceeding 5%. The wide analyst EPS range underscores the current lack of visibility.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Pfizer's 12-month outlook, with a consensus price target around $33.22 and implied upside of +30.0% versus the current price.
Average Target
$33.22
11 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
11
covering this stock
Price Range
$20 - $33
Analyst target range
Analyst coverage for Pfizer is limited, with only 11 analysts providing estimates, indicating a stock that, despite its large market cap, may have reduced institutional focus following its post-pandemic narrative shift. The consensus sentiment, inferred from recent institutional ratings, appears mixed but leans cautiously positive, with firms like Guggenheim and HSBC maintaining 'Buy' ratings while others like Morgan Stanley and BofA Securities have 'Equal-Weight' or 'Neutral' stances, reflecting uncertainty about the near-term growth path. The target price range is not explicitly provided in the analyst data, but the wide dispersion in estimated EPS for the next period, with a low of $2.29 and a high of $2.51, signals meaningful disagreement on the company's earnings power, which translates to high uncertainty and a lack of strong conviction on the stock's fair value.
Bulls vs Bears: PFE Investment Factors
The evidence currently tilts bearish, as the company's fundamental challenges—unsustainable dividend, volatile earnings, and revenue decline—outweigh its attractive valuation and defensive characteristics. The most critical tension in the investment debate is the sustainability of the high dividend yield. If management can stabilize earnings and cover the payout with sustainable cash flow, the stock's deep value could be unlocked. However, if profitability continues to deteriorate, forcing a dividend cut, the stock could re-test its 52-week low, representing significant downside from current levels.
Bullish
- Attractive Forward Valuation: The forward P/E ratio of 9.23 is exceptionally low for a major pharmaceutical company, suggesting the market has priced in significant pessimism. This valuation is based on analyst consensus EPS of $2.40, implying a recovery from recent quarterly losses.
- Strong Free Cash Flow Generation: The company generates substantial cash, with trailing twelve-month free cash flow of $9.08 billion. This provides a solid foundation for funding its dividend, R&D pipeline, and strategic acquisitions to drive future growth.
- Recent Pipeline & Patent Wins: Recent FDA approval for the breast cancer therapy VEPPANU and a patent settlement extending Vyndamax protection to 2031 are tangible near-term and long-term catalysts. These developments validate the R&D strategy and mitigate the feared revenue cliff from key products.
- High Dividend Yield: The current dividend yield of 6.9% is significantly above the market average, providing a substantial income cushion for investors. This yield is supported by the company's massive scale and cash flow, even as payout sustainability is under scrutiny.
Bearish
- Unsustainable Dividend Payout: The dividend payout ratio of 125.75% exceeds earnings, and recent news highlights negative free cash flow coverage. This creates a significant risk of a dividend cut if profitability does not recover, which would likely trigger a sharp sell-off.
- Persistent Revenue & Earnings Decline: Q4 2025 revenue declined 1.16% YoY, and net income swung to a loss of -$1.65 billion from a $3.54 billion profit the prior quarter. This volatility and top-line pressure underscore the challenging post-COVID transition and lack of clear growth momentum.
- Severe Relative Underperformance: The stock has dramatically underperformed the market, with a 1-year relative strength of -16.57% and a 3-month decline of 5.32% versus the S&P 500's 10.28% gain. This reflects a complete loss of investor confidence and a lack of positive catalysts.
- Analyst Uncertainty & Lack of Conviction: Only 11 analysts cover the stock, and their EPS estimates for the next period range widely from $2.29 to $2.51. This high dispersion signals a lack of consensus on the company's earnings power and translates to low institutional conviction.
PFE Technical Analysis
The stock is in a pronounced downtrend, evidenced by a 1-year price change of +11.64% that significantly underperforms the broader market, as indicated by a relative strength of -16.57. Currently trading at $26.18, the price sits at approximately 63% of its 52-week range ($23.06 to $28.75), indicating it is positioned closer to the lower bound, which may suggest a value opportunity but also reflects persistent selling pressure and a lack of bullish momentum. Recent momentum is decisively negative, with the stock down 0.30% over the past month and down 5.32% over the past three months, starkly diverging from the S&P 500's gains of 6.31% and 10.28% over the same periods, respectively, highlighting severe relative weakness and a failure to participate in the broader market rally. The stock's beta of 0.305 indicates it is roughly 70% less volatile than the market, which, while reducing downside risk during sell-offs, also limits its potential for explosive rebounds. Key technical support is clearly defined at the 52-week low of $23.06, while immediate resistance lies near the recent high of $28.75; a sustained breakdown below $23.06 would signal a new leg down, whereas a breakout above $28.75 is needed to suggest a meaningful trend reversal is underway.
Beta
0.30
0.30x market volatility
Max Drawdown
-11.5%
Largest decline past year
52-Week Range
$23-$29
Price range past year
Annual Return
+8.9%
Cumulative gain past year
| Period | PFE Return | S&P 500 |
|---|---|---|
| 1m | -3.0% | +5.4% |
| 3m | -4.0% | +10.9% |
| 6m | -0.6% | +11.0% |
| 1y | +8.9% | +28.1% |
| ytd | +1.5% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PFE Fundamental Analysis
Pfizer's revenue trajectory is currently under pressure, with Q4 2025 revenue of $17.56 billion representing a year-over-year decline of 1.16%, continuing a multi-quarter trend of deceleration as the company laps the windfall from its COVID-19 products. The quarterly net income of -$1.65 billion and a gross margin of 69.97% for Q4 2025 reflect significant profitability challenges, though the gross margin remains robust and in line with historical pharmaceutical industry norms; however, the sharp swing from a net income of $3.54 billion in the prior quarter underscores the earnings volatility and the impact of one-time charges or revenue declines. The company's balance sheet and cash flow position show mixed signals, with a manageable debt-to-equity ratio of 0.78 and a current ratio of 1.16 indicating adequate short-term liquidity, but the trailing twelve-month free cash flow of $9.08 billion, while substantial, must be viewed in the context of a dividend payout ratio of 125.75%, which exceeds earnings and raises questions about the sustainability of shareholder returns without improved profitability.
Quarterly Revenue
$17.6B
2025-12
Revenue YoY Growth
-0.01%
YoY Comparison
Gross Margin
+0.69%
Latest Quarter
Free Cash Flow
$9.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PFE Overvalued?
Given the negative net income in the most recent quarter, the primary valuation metric selected is the Price-to-Sales (PS) ratio. Pfizer's trailing PS ratio is 2.26, while its forward PE ratio, based on positive estimated earnings, is 9.23; the significant discount of the forward PE suggests the market is pricing in a recovery to profitability, but the current sales multiple reflects the top-line pressures. Compared to industry averages, specific peer data is not provided in the valuation dataset, so a direct sector premium/discount cannot be quantified; however, a PS ratio of 2.26 for a large-cap pharmaceutical company appears reasonable and may not imply a significant premium, pending growth and margin comparisons. Historically, the stock's own valuation shows the current trailing PE ratio of 18.21 is above the deeply negative PE from Q4 2025 but below the elevated levels seen during peak profitability periods in 2022-2023, placing it in a middle ground that reflects subdued, but not catastrophic, expectations for earnings normalization.
PE
18.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -21x~1666x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are centered on earnings volatility and dividend sustainability. The Q4 2025 net loss of -$1.65 billion, following a $3.54 billion profit in Q3, highlights extreme earnings unpredictability. The dividend payout ratio of 125.75% is a major red flag, as the dividend is not covered by earnings, creating a high probability of a cut if free cash flow generation weakens. Furthermore, revenue declined 1.16% YoY in the latest quarter, indicating the core business is struggling to grow post-COVID, which pressures margins and valuation.
Market & Competitive Risks include intense competition in high-growth therapeutic areas where Pfizer lacks a strong presence, such as the obesity drug market dominated by Eli Lilly. The stock's severe underperformance (relative strength of -16.57% over 1 year) suggests it is being shunned by growth investors in favor of sector peers with clearer growth narratives. While the low beta of 0.305 offers some defense, it also means the stock may not participate in market rallies, leading to prolonged stagnation. The wide analyst EPS estimate range (low $2.29 to high $2.51) reflects high uncertainty, which can lead to sharp price moves on earnings misses.
Worst-Case Scenario involves a continuation of revenue declines, coupled with a failure of new drug launches to gain traction. This could lead to a credit rating downgrade due to its $0.78 debt-to-equity ratio, forcing asset sales. The most damaging event would be a dividend cut, which would trigger massive selling from income-focused funds. In this adverse scenario, the stock could realistically fall to its 52-week low of $23.06, representing a downside of approximately -12% from the current price of $26.18. A breach of that support could lead to a further decline towards $20, representing a total potential loss of -24%.
FAQ
The key risks are, in order of severity: 1) Dividend Sustainability Risk: The payout ratio of 125.75% is dangerously high, making a cut a real possibility. 2) Revenue Decline Risk: Core business revenue fell 1.16% YoY, with no clear catalyst for growth. 3) Competitive & Pipeline Risk: Pfizer is not a leader in high-growth areas like obesity drugs, and its pipeline must deliver to offset patent expirations. 4) Sentiment Risk: The stock has severely underperformed the market (relative strength -16.57% over 1 year), indicating a complete loss of investor favor that could persist.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $26 and $28, as the company stabilizes but fails to grow. The Bull Case (25% probability) targets $30 to $32 on successful new drug launches and dividend security. The Bear Case (15% probability) warns of a drop to $21-$23 on a dividend cut and worsening fundamentals. The Base Case is most likely, anchored by analyst consensus EPS of $2.40, but the wide estimate range indicates high forecast uncertainty.
Based on forward earnings, PFE appears significantly undervalued, trading at a forward P/E of just 9.23. This is a deep discount compared to historical pharmaceutical company averages. However, this low multiple reflects justified pessimism about near-term growth and dividend sustainability. On a trailing basis, the P/E of 18.21 is more reasonable but still depressed. The market is valuing PFE as a company in decline, making it undervalued only if management can successfully execute a return to stable growth.
PFE is a high-risk, high-potential-reward stock that may be a good buy only for specific investors. Its forward P/E of 9.23 and dividend yield of 6.9% are highly attractive. However, the dividend payout ratio of 125.75% is unsustainable, and revenue declined 1.16% in the last quarter. It could be a good buy for patient, value-oriented income investors willing to bet on a turnaround, but it is not suitable for growth investors or those seeking stability, as a dividend cut could lead to significant short-term losses.
PFE is strictly a long-term investment, with a suggested minimum holding period of 3-5 years. Its low beta of 0.305 means it lacks volatility for short-term trading. The investment thesis hinges on a multi-year turnaround where new products gain market share and the dividend is secured. The high yield provides an income stream while waiting, but the stock could remain depressed in the near term. It is unsuitable for short-term traders seeking momentum or quick gains, as positive catalysts are likely quarters, if not years, away.